30 related articles for article (PubMed ID: 36516883)
21. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression.
Zeng F; Li Y; Meng Y; Sun H; He Y; Yin M; Chen X; Deng G
Exp Mol Med; 2023 Feb; 55(2):364-376. PubMed ID: 36720918
[TBL] [Abstract][Full Text] [Related]
22. BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway.
Hu R; Li Y; Guo Y; Li X; Du S; Liao M; Hou H; Sun H; Zhao S; Su J; Chen X; Yin M
Pharmacol Res; 2023 Jan; 187():106609. PubMed ID: 36516883
[TBL] [Abstract][Full Text] [Related]
23. The mechanisms behind the therapeutic activity of BET bromodomain inhibition.
Shi J; Vakoc CR
Mol Cell; 2014 Jun; 54(5):728-36. PubMed ID: 24905006
[TBL] [Abstract][Full Text] [Related]
24. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
25. BRD4 in physiology and pathology: ''BET'' on its partners.
Liang Y; Tian J; Wu T
Bioessays; 2021 Dec; 43(12):e2100180. PubMed ID: 34697817
[TBL] [Abstract][Full Text] [Related]
26. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
27.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
28.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
29.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
